3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
2
Interventions
Trastuzumab
243
Paclitaxel
193
Cyclophosphamide
158
Docetaxel
134
Letrozole
113
Capecitabine
113
Fulvestrant
106
Doxorubicin
103
Bevacizumab
87
Carboplatin
81
exemestane
80
Anastrozole
79
Lapatinib
70
Tamoxifen
69
Albumin-Bound Paclitaxel
57
palbociclib
54
pertuzumab
53
Taxes
51
Gemcitabine
50
Radiotherapy
46
eribulin
43
pembrolizumab
41
Everolimus
41
Ado-Trastuzumab Emtansine
41
Vinorelbine
38
130-nm albumin-bound paclitaxel
35
ixabepilone
32
Epirubicin
28
pegfilgrastim
25
liposomal doxorubicin
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Breast Neoplasms
×
AZD 8931
×
Clear all
NCT00900627
2016-01-20
THYME
AstraZeneca
Phase 1/2
Completed
330 enrolled
20 charts
NCT01151215
2014-07-25
MINT
AstraZeneca
Phase 2
Terminated
482 enrolled
10 charts